Filters

 

Resource Type
Nav1.5 late current in WT and Nav1.5-ΔKPQ mutant channels: an automated patch clamp LQT3 electrophysiological assay comparison

The cardiac late Na+ current (late INa) generates persistent inward currents throughout the plateau phase of the ventricular action potential and is an important determinant of repolarisation rate, EADs and arrythmia risk¹. As inhibition of late INa can offset drug effects on hERG and other repolarising K⁺conductances, it is one of the key cardiac channels in the Comprehensive in vitro Pro-arrythmia Assay (CiPA) panel being developed by the FDA to improve human clinical arrythmia risk assessment²̛ ³.

Read More
Development of an impedance-based screening assay for cardiac safety and cardiotoxicity detection in stem cell-derived cardiomyocytes

Cardiac toxicity remains the leading cause of new drug safety side-effects. Current preclinical cardiac safety assays rely on in vitro cell-based ion channel assays and ex vivo and in vivo animal models⁽¹⁾. These assays provide an indication of acute risk but they do not always predict the effect of chronic compound exposure, as recently seen with oncology drugs. Therefore, new assays are required to characterise chronic structural and functional effects in human cells earlier in drug discovery. Impedance-based technology can provide more accurate chronic cardiotoxicity measurements in an efficient manner using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).

Read More
Reduce the chance of late-stage failures due to cardiac toxicity

By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity

Read More
Development of Automated Electrophysiology Assays for the Characterisation of Inhibitors Against Human HCN Ion Channels

We demonstrate the generation and validation of a stable CHO-hHCN2 cell line used as a cellular tool in the successful development of hHCN2 automated electrophysiology screening assays.

Read More
Seal enhancers on the Qube 384: An alternative to F

Metrion and Sophion collaborated to determine whether other insoluble salts can act as seal enhancers, or whether this property is unique to CaF2.

Read More
What is the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative?

CiPA logoThe International Council on Harmonization (ICH) S7B and E14 regulatory guidelines were introduced in 2005 to evaluate the proarrhythmic liability of new drugs.

Read More
Webinar recording - Accelerating Pain Therapeutic Discovery: Nav1.9 as a Drug Target for Treatment of Pain

Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.

Read More
Development of a High-Throughput Automated Electrophysiology Assay for Human Nav1.9 Inhibitor Screening

Alex Haworth, Senior Scientist at Metrion, introduces a poster demonstrating Metrion's development of a monoclonal CHO cell line expressing hNav1.9, validated via manual and automated patch clamp techniques.

Read More
Introduction to ion channel screening at Metrion

Introduction to ion channel screening at Metrion

Read More
Introduction to neuroscience at Metrion

Introduction to neuroscience at Metrion

Read More
1 2 3 15
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram